Algerian pharmaceutical company, صيدال, has launched a new medication, دابافلوكس, to treat type 2 diabetes patients. The launch took place during a scientific conference in Algiers, under the slogan "تقارب: مقاربة مشتركة" (Convergence: A Shared Approach). The event was attended by officials from the pharmaceutical industry, professors, and specialized doctors, as well as representatives from the Ministry of Pharmaceutical Industry.

The conference was held under the supervision of the General Director of صيدال, يونس بوعرعارة, and in the presence of the General Secretary of the Ministry of Pharmaceutical Industry, عبد الحكيم بوالديس, representing the Minister of the sector, وسيم قويدري. Other attendees included the General Director of the National Agency for Pharmaceutical Materials, شريف دليح, and Professor عمار طبايبية, head of the multidisciplinary expert committee tasked with advising on the national list of essential medicines.

In his speech, the General Director of صيدال emphasized that the launch of دابافلوكس represents a new milestone in the company's development path. He stated that it aligns with the company's strategy to diversify therapeutic areas, enhance industrial and technological capabilities, and promote innovation in the pharmaceutical industry. The company reiterated its commitment to providing high-quality medications at affordable prices to improve healthcare and increase access to treatments.

The General Secretary of the Ministry of Pharmaceutical Industry, speaking on behalf of the Minister, highlighted the importance of adopting a comprehensive approach to managing type 2 diabetes. This approach focuses on early detection, regular medical follow-up, and prevention of cardiovascular and kidney complications. He emphasized that this direction is part of the strategic vision of the President of the Republic, عبد المجيد تبون, aimed at enhancing health sovereignty and improving the management of chronic diseases.

The launch of دابافلوكس is part of efforts to expand the list of available treatments for type 2 diabetes patients and increase the contribution of national production to meeting citizens' healthcare needs. This development aligns with the company's goal of providing high-quality medications at affordable prices, thereby improving healthcare and increasing access to treatments for patients.

The new medication is expected to play a significant role in managing type 2 diabetes in Algeria. The country's pharmaceutical industry has been working to enhance its capabilities and promote innovation in recent years. The launch of دابافلوكس demonstrates the progress being made in this sector and the commitment to improving healthcare outcomes for patients.

The development and launch of دابافلوكس reflect the collaborative efforts between the pharmaceutical industry, healthcare professionals, and government agencies in Algeria. These efforts aim to improve the management of chronic diseases, such as diabetes, and enhance the overall quality of healthcare in the country. The launch of this new medication is a significant step towards achieving these goals.

Key points

  • The new medication, دابافلوكس, is designed to treat type 2 diabetes patients and is part of صيدال's strategy to diversify therapeutic areas and promote innovation in the pharmaceutical industry.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.